Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis.

Pediatric nephrology (Berlin, Germany) - 1 Feb 2021

Klämbt Verena, Gimpel Charlotte, Bald Martin, Gerken Christopher, Billing Heiko, Loos Sebastian, Hansen Matthias, König Jens, Vinke Tobias, Montoya Carmen, Lange-Sperandio Bärbel, Kirschstein Martin, Hennies Imke, Pohl Martin, Häffner Karsten

Abstract excerpt

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening microangiopathy, frequently causing kidney failure. Inhibition of the terminal complement complex with eculizumab is the only licensed treatment but mostly requires long-term administration and risks severe side effects. The underlying genetic cause of aHUS is thought to influence the severity of initial and recurring episodes, with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atypical Hemolytic Uremic Syndrome
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Kidney Failure, Chronic

Share to Membrane Cofactor Protein

Share to Mutation

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 32715379
DOI: 10.1007/s00467-020-04714-0
PMCID: PMC7815604

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis.PMID 32715379Read ↗

Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.Semantic proximity Read ↗

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.Semantic proximity Read ↗

Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.Semantic proximity Read ↗

A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.Semantic proximity Read ↗

Genetic atypical hemolytic uremic syndrome in children: a 20-year experience from a tertiary center.Semantic proximity Read ↗

Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeSemantic proximity Read ↗

Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome.Semantic proximity Read ↗

Underlying Genetics of aHUS: Which Connection with Outcome and Treatment Discontinuation?Semantic proximity Read ↗

Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients.Semantic proximity Read ↗

Adolescence-onset atypical hemolytic uremic syndrome: is it different from infant-onset?Semantic proximity Read ↗

An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus documentSemantic proximity Read ↗

Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.